Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson's disease models

被引:13
|
作者
Liu, Lan-Xiang [1 ]
Du, Dan [1 ]
Wang, Zhan-Qiu [1 ]
Fang, Yuan [1 ]
Zheng, Tao [1 ]
Dong, Yan-Chao [2 ]
Shi, Qing-Lei [3 ]
Zhao, Min [4 ]
Xiao, Fang [4 ]
Du, Juan [5 ]
机构
[1] Qinhuangdao Municipal 1 Hosp, Dept Magnet Resonance Imaging, Qinhuangdao, Hebei, Peoples R China
[2] Qinhuangdao Municipal 1 Hosp, Dept Intervent, Qinhuangdao, Hebei, Peoples R China
[3] Siemens Ltd, Beijing, Peoples R China
[4] Qinhuangdao Municipal 1 Hosp, Dept Pathol, Qinhuangdao, Hebei, Peoples R China
[5] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China
关键词
nerve regeneration; fractional anisotropy; T2*; rotenone; 6-hydroxydopamine; Parkinson's disease; magnetic resonance imaging; diffusion tensor imaging; dopaminergic neurons; neural regeneration; WHITE-MATTER CHANGES; SUBSTANTIA-NIGRA; COMPLEX-I; DEGENERATION; MECHANISMS; DEPOSITION; TOXICITY; SYSTEM;
D O I
10.4103/1673-5374.235076
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson's disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characteristics of these two models by magnetic resonance imaging. In this study, rat models of Parkinson's disease were generated by injection of 3 mu g rotenone or 10 mu g 6-hydroxydopamine into the right substantia nigra. At 1, 2, 4, and 6 weeks after injection, coronal whole-brain T2-weighted imaging, transverse whole-brain T2-weighted imaging, and coronal diffusion tensor weighted imaging were conducted to measure fractional anisotropy and T2* values at the injury site. The fractional anisotropy value on the right side of the substantia nigra was remarkably lower at 6 weeks than at other time points in the rotenone group. In the 6-hydroxydopamine group, the fractional anisotropy value was decreased, but T2* values were increased on the right side of the substantia nigra at 1 week. Our findings confirm that the 6-hydroxydopamine-induced model is suitable for studying dopaminergic neurons over short periods, while the rotenone-induced model may be appropriate for studying the pathological and physiological processes of Parkinson's disease over long periods.
引用
收藏
页码:1276 / 1280
页数:5
相关论文
共 50 条
  • [1] Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson's disease models
    Lan-Xiang Liu
    Dan Du
    Zhan-Qiu Wang
    Yuan Fang
    Tao Zheng
    Yan-Chao Dong
    Qing-Lei Shi
    Min Zhao
    Fang Xiao
    Juan Du
    Neural Regeneration Research, 2018, 13 (07) : 1276 - 1280
  • [2] The 6-hydroxydopamine model of Parkinson's disease
    Simola, Nicola
    Morelli, Micaela
    Carta, Anna R.
    NEUROTOXICITY RESEARCH, 2007, 11 (3-4) : 151 - 167
  • [3] The 6-Hydroxydopamine model of parkinson’s disease
    Nicola Simola
    Micaela Morelli
    Anna R. Carta
    Neurotoxicity Research, 2007, 11 : 151 - 167
  • [4] Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease
    Henning, Jeannette
    Strauss, Ulf
    Wree, Andreas
    Gimsa, Jan
    Rolfs, Arndt
    Benecke, Reiner
    Gimsa, Ulrike
    NEUROSCIENCE RESEARCH, 2008, 62 (04) : 246 - 253
  • [5] Mechanisms underlying pathological oscillations in the rat 6-hydroxydopamine model of Parkinson's disease
    Escande, M. V.
    Zold, C. L.
    Riquelme, L. A.
    Belforte, J. E.
    Murer, M. G.
    MOVEMENT DISORDERS, 2010, 25 (07) : S339 - S340
  • [6] Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP
    Grünblatt, E
    Mandel, S
    Youdim, MBH
    REACTIVE OXYGEN SPECIES: FROM RADIATION TO MOLECULAR BIOLOGY: A FESTSCHRIFT IN HONOR OF DANIEL L GILBERT, 2000, 899 : 262 - 273
  • [7] The 6-hydroxydopamine Rat Model of Parkinson's Disease
    Guimaraes, Rayanne Poletti
    Ribeiro, Danilo Leandro
    dos Santos, Keila Bariotto
    Godoy, Livea Dornela
    Correa, Mirella Rosine
    Padovan-Neto, Fernando Eduardo
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (176):
  • [8] Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease
    Zhou, Ming
    Zhang, Wangming
    Chang, Jingyu
    Wang, Jun
    Zheng, Weixin
    Yang, Yong
    Wen, Peng
    Li, Min
    Xiao, Hu
    NEUROSCIENCE LETTERS, 2015, 584 : 184 - 189
  • [9] Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease
    Sadeghian, M.
    Mullali, G.
    Pocock, J. M.
    Piers, T.
    Roach, A.
    Smith, K. J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (05) : 423 - 435
  • [10] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson’s Disease
    Sang J. Na
    Anthony G. DiLella
    Edward V. Lis
    Keith Jones
    David M. Levine
    David J. Stone
    J. F. Hess
    Neurochemical Research, 2010, 35 : 761 - 772